STOCK TITAN

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Collegium Pharmaceutical (Nasdaq: COLL) has reached a settlement framework to resolve 27 opioid-related lawsuits for a maximum payment of $2,750,000. This agreement aims to dismiss all pending cases while ensuring no admission of liability. The settlement, which awaits final approval, reflects the company's commitment to responsible pain management. Executive VP Shirley Kuhlmann expressed satisfaction with the resolution, indicating a focus on future operations free from this litigation burden.

Positive
  • Settlement framework to resolve 27 opioid-related lawsuits for up to $2.75 million.
  • No admission of liability, allowing for potential future operational focus.
Negative
  • None.

STOUGHTON, Mass., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States. The settlement framework provides for the Company to pay an amount not to exceed $2,750,000 in exchange for the dismissal, with prejudice, of all 27 pending cases and a release from liability related to the dismissed cases. The Company entered into the settlement framework, which is subject to approval by all parties of a final settlement agreement, to efficiently resolve this litigation, and the framework is not an admission of any liability or wrongdoing.

“We are pleased to be in a position to resolve these cases and move forward. We remain committed to our mission of being the leader in responsible pain management,” said Shirley Kuhlmann, Executive Vice President, General Counsel of Collegium.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the potential resolution of certain litigation matters and the Company’s plans to continue to defend against future litigation. Any forward-looking statements in this press release could be affected by risks and uncertainties relating to a number of factors, including the litigation strategy and preferences of the plaintiffs that have brought lawsuits against the Company and developments in the opioid industry litigation broadly. These and other risks are described under the heading “Risk Factors” in our most recent Quarterly Report on Form 10-Q and subsequent filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


FAQ

What did Collegium Pharmaceutical announce on December 28, 2021?

Collegium Pharmaceutical announced a settlement framework for 27 opioid-related lawsuits, agreeing to pay up to $2.75 million.

What is the total amount Collegium Pharmaceutical is set to pay in the settlement?

Collegium Pharmaceutical is set to pay an amount not to exceed $2,750,000 to resolve the lawsuits.

Did Collegium Pharmaceutical admit any liability in the settlement?

No, the settlement framework includes no admission of liability or wrongdoing.

How many lawsuits is Collegium Pharmaceutical settling?

Collegium Pharmaceutical is settling 27 pending opioid-related lawsuits.

What is Collegium Pharmaceutical's commitment regarding pain management?

Collegium Pharmaceutical is committed to being a leader in responsible pain management.

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

COLL Rankings

COLL Latest News

COLL Stock Data

957.99M
32.25M
1.32%
129.19%
19.08%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
BRISBANE